8-K: Myomo Reports 162% Revenue Increase in First Quarter 2025, Driven by MyoPro Adoption

Myomo, Inc. announced a significant revenue increase of 162% in Q1 2025, reaching $9.8 million, fueled by growing adoption of its MyoPro devices.

Summary

• Myomo, Inc. reported its financial results for the first quarter ended March 31, 2025.
• Revenue reached $9.8 million, a 162% increase compared to the first quarter of 2024.
• The company recognized revenue on 182 MyoPro units, up 100% year-over-year.
• Gross margin improved to 67.2%, up from 61.2% in the same period last year.
• The operating loss was $3.5 million, an improvement from the $3.9 million loss in Q1 2024.
• The net loss was $3.5 million, or $0.08 per share, compared to a net loss of $3.8 million, or $0.10 per share, in the first quarter of 2024.
• Adjusted EBITDA was $(2.8) million, compared to $(3.5) million in the first quarter of 2024.
• The patient pipeline grew to 1,482 candidates, a 33% increase year-over-year, with a record 700 new candidates added in the quarter.
• The company received orders and insurance authorizations for 213 MyoPro units, up 18% compared to the same period a year ago.
• Backlog decreased by 9% to 249 units as of March 31, 2025.
• Cash, cash equivalents, and short-term investments totaled $21.5 million as of March 31, 2025.
• The company expects Q2 revenue to be in the range of $9.0 million to $9.5 million.
• Full-year revenue is projected to be between $50 million and $53 million, representing a 54% to 63% increase compared to 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company shows strong revenue growth and pipeline expansion, but also faces challenges with operating expenses and lead generation costs. The future outlook is optimistic, but dependent on successful execution.

Positives

• Revenue increased significantly by 162% to $9.8 million.
• Gross margin improved to 67.2%.
• The patient pipeline grew by 33% to 1,482 candidates.
• A record 700 new candidates were added to the patient pipeline.
• Orders and insurance authorizations increased by 18% to 213 MyoPro units.
• ASP increased 31% to approximately $54,000.

Negatives

• The backlog decreased by 9% to 249 units.
• Operating expenses increased by 64% to $10.1 million.
• The cost per pipeline add increased by 31% to $2,300 due to social media algorithm changes.
• Cash decreased by approximately $3.3 million compared with December 31, 2024.

Risks

• Continued utilization management by Medicare Advantage plans impacted authorizations and orders.
• Changes to social media algorithms disrupted lead flow and increased the cost per pipeline add.
• The company's ability to obtain sufficient reimbursement from third-party payers for its products is a risk.
• The company's dependence upon external sources for the financing of its operations is a risk.

Future Outlook

Myomo expects second quarter revenue to be in the range of $9.0 million to $9.5 million and continues to expect full-year revenue to be in the range of $50 million to $53 million, an increase of 54% to 63% compared with 2024.

Management Comments

• 'Our first quarter financial results were in line with expectations, yet several operating metrics were affected by continued utilization management by Medicare Advantage plans which impacted authorizations and orders, as well as changes to social media algorithms that disrupted lead flow and increased our cost per pipeline add during the first six weeks of the quarter.'
• 'I'm pleased to report that both lead flow and pipeline adds rebounded in March and April,' said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer.

Industry Context

Myomo operates in the wearable medical robotics industry, focusing on upper-limb orthoses. The company's growth is tied to the adoption of its MyoPro device and reimbursement policies from insurers, particularly Medicare.

Comparison to Industry Standards

• It is difficult to compare Myomo directly to industry standards as it is currently the only marketed device in the U.S. that, sensing a patients own EMG signals through non-invasive sensors on the arm, can restore an individuals ability to perform activities of daily living.
• Other companies in the broader medical device and rehabilitation robotics space, such as Ekso Bionics and ReWalk Robotics, focus on different applications like lower-limb exoskeletons.
• Myomo's revenue growth of 162% in Q1 2025 suggests strong market demand for its MyoPro device, but its continued operating losses indicate the need for further scaling and cost management.

Stakeholder Impact

• Shareholders will be encouraged by the strong revenue growth but concerned about the continued operating losses.
• Employees may benefit from the company's growth and expansion.
• Patients will have increased access to MyoPro devices.
• Suppliers may see increased demand for components and materials.
• Creditors will monitor the company's cash position and ability to achieve profitability.

Next Steps

• Myomo will hold a conference call to discuss the results and answer questions.
• The company will focus on accelerating revenue growth in the second half of 2025.
• Myomo will continue to manage costs and improve lead generation strategies.

Key Dates

Keywords

Myomo, MyoPro, wearable robotics, upper-limb paralysis, financial results, revenue, gross margin, patient pipeline, Medicare, orthosis